Syndecan-1 Expression Inhibits the Development of Myeloma-Induced Morbidity in scid Mice
| Cells . | N . | Morbidity (%)-150 . | Mean Time to Morbidity . | Lytic Lesions (%) . |
|---|---|---|---|---|
| ARH-77neo | 20 | 85 | 58 d | 80 |
| ARH-77syn-1 | 20 | 35-151 | 84 d-151 | 30-151 |
| Cells . | N . | Morbidity (%)-150 . | Mean Time to Morbidity . | Lytic Lesions (%) . |
|---|---|---|---|---|
| ARH-77neo | 20 | 85 | 58 d | 80 |
| ARH-77syn-1 | 20 | 35-151 | 84 d-151 | 30-151 |
Male CB.17 scid mice were injected with ARH-77 cells transfected with either a control vector or full-length syndecan-1 construct and monitored for the development of disease-related morbidity. Development of lytic bone disease was evaluated with skeletal radiographs.
Defined as hind limb paralysis, visible tumors, or extreme emaciation and lethargy.
Statistically significant.